Condition: Alzheimer Disease · Frontotemporal Dementia · Dementia · Sponsor: David Wilson
This is a first in human study that will assess the safety and diagnostic performance of \[18F\]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD).
This description comes directly from the study's public registry record.
David Wilson, MD, PhD · 415-514-6229 · david.m.wilson@ucsf.edu
Henry Vanbrocklin, PhD · 415-353-4569 · henry.vanbrocklin@ucsf.edu
Always discuss trial participation with your own doctor first.
| China Basin, UCSF | San Francisco, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05374278